[Phosphodiesterase type 5 inhibitors for lower urinary tract symptoms induced by benign prostatic hyperplasia: an update].

Abstract

Medication has become the first-line option for the management of lower urinary tract symptoms induced by benign prostatic hyperplasia (LUTS/BPH) for its advantages in controlling the symptoms, inhibiting BPH progression, and reducing serious complications and surgical risks. Recent years have witnessed remarkable achievement in the studies of phosphodiesterase type 5 inhibitors (PDE5-Is) in the treatment of LUTS/BPH. PDE5-Is can effectively alleviate LUTS/BPH, with even better efficacy when combined with al-ARAs.

• Authors: Peng-Bin He, Pei-Jin Zha, Dong-Ping Xu
• Journal: Zhonghua nan ke xue = National journal of andrology (Zhonghua Nan Ke Xue) Vol. 20 Issue 7 Pg. 651-6 (Jul 2014) ISSN: 1009-3591 [Print] China
• PMID: 25095624 (Publication Type: English Abstract, Journal Article, Review)

Chemical References

• Phosphodiesterase 5 Inhibitors

Topics

• Humans
• Lower Urinary Tract Symptoms (drug therapy, etiology)
• Male
• Phosphodiesterase 5 Inhibitors (therapeutic use)
• Prostatic Hyperplasia (complications)